Get started
Author

María José Juan-Fita

Observed names: M.J. Juan Fita, Maria J. FITA, Maria J. Juan Fita, Maria Jose Juan FITA, Maria Jose Juan Fita, Maria José Juan Fita, María J. Juan Fita, María José Juan Fita
ORCID: 0000-0002-7767-0200
Observed ORCID: 0000-0002-7767-0200
OpenAlex ID: A5102952341
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
2021 · Thomas Powles, Tibor Csőszi, et al. · The Lancet Oncology · 665
MicroRNA signatures in hereditary breast cancer
2013 · Rosa Murria Estal, Sarai Palanca Suela, et al. · Breast Cancer Research and Treatment · 44
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study
2015 · B. Pérez-Valderrama, J.A. Arranz Arija, et al. · Annals of Oncology · 40
Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer
2018 · Beatriz Paumard‐Hernández, Oriol Calvete, et al. · International Journal of Cancer · 33
PDF
Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study
2023 · Alicia López-Abad, Miguel Ramírez Backhaus, et al. · Prostate International · 27
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025 · Xavier Garcia-del-Muro, Begoña P. Valderrama, et al. · Clinical Cancer Research · 21
Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial
2017 · Miguel Ángel Climent, Begoña Pérez-Valderrama, et al. · European Journal of Cancer · 21
Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study
2024 · Alicia López-Abad, Mario Belmonte, et al. · Journal of Clinical Medicine · 15
PDF
Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer
2016 · Rosa Murria Estal, Sarai Palanca Suela, et al. · Familial Cancer · 15
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
2022 · Miguel A. Climent, Albert Font, et al. · European Journal of Cancer · 13
PDF
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database
2024 · Mario Hassi Roman, Kinga Mate, et al. · European Urology Open Science · 11
Advanced systemic amyloidosis secondary to metastatic renal cell carcinoma
2020 · Maria Asunción Algarra, Maria José Juan Fita, et al. · ecancermedicalscience · 11
PDF
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study
2025 · Francesco Massari, Matteo Rosellini, et al. · JCO Global Oncology · 9
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
2025 · Francesco Massari, Veronica Mollica, et al. · European Urology Focus · 7
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study
2023 · Sebastian Ochenduszko, Javier García Sanchez, et al. · Pigment Cell & Melanoma Research · 6
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
2026 · Philipp Cornelius Mandel, Mike Wenzel, et al. · European Urology Oncology · 5
Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC
2025 · Ángel Borque-Fernando, Teresa Alonso-Gordoa, et al. · Future Oncology · 4
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors
2026 · Philipp Mandel, Mike Wenzel, et al. · European Urology Open Science · 3
Phase II trial evaluating olaparib maintenance in patients with metastatic castration resistant prostate cancer (mCRPC) after docetaxel treatment, reaching partial or stable response: SOGUG-IMANOL study.
2023 · Maria Jose Juan FITA, Urbano Anido Herranz, et al. · Journal of Clinical Oncology · 3
PDF
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
2025 · Cristina Suárez, Òscar Reig Torras, et al. · Clinical Genitourinary Cancer · 2
Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.
2020 · Miguel Angel Climent Duran, Albert Font, et al. · Journal of Clinical Oncology · 2
Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naïve castration-resistant prostate cancer: Exploratory results from PREMIERE—A SOGUG trial.
2017 · Albert Font Pous, Sergio Vazquez-Estevez, et al. · Journal of Clinical Oncology · 2
Locoregional relapse in BRCA1/2 breast cancer women treated with breast-conserving surgery.
2016 · María José Juan Fita, Isabel Chirivella, et al. · Journal of Clinical Oncology · 2
JEVTCC: Phase II trial of cabazitaxel (Cbz) in patients (pt) with advanced or metastatic transitional-cell carcinoma (mTCC), who progressed before 12 months after cisplatin-based chemotherapy—A Spanish Oncologic Genitourinary Group (SOGUG) study.
2015 · Jose Angel Arranz Arija, Xavier Garcia del Muro, et al. · Journal of Clinical Oncology · 2
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
2026 · Evelyn L. Beas-Lozano, Sarah Scagliarini, et al. · Frontiers in Immunology · 1
PDF
Works count: 68
Citation count: 972
H-index: 11
I10-index: 12
Year
Topic
Type